Pharmaceutical products for human or veterinary use.
New drugs developed as a result of translational research is a critical component of the emphasis to improve and reduce the process of scientific discovery to useful clinical applications. A review of the drug development timeline can identify successful research process practices to be utilized by other translational science research teams.
Advice from authors on searching for information:
Self-reported knowledge of research study researchers is helpful to document new drug development in progress and for tracking drugs that have demonstrated efficacy in pre-clinical or clinical studies, those that have gained FDA approval, or those that are currently in use in clinical applications for the treatment of a disease, condition, or disorder.
Resources & Data
Organizations, repositories, websites, and other sources where you can find more information:
- Center for Research Innovation in Biotechnology. The Center for Research Innovation in Biotechnology provides a database of new molecular entities approved by the FDA, including information on their sponsors, indications, and targets.
- Office of Technology Management at Washington University (OTM). The OTM Technology Catalog allows for searching of new drugs developed by researchers at Washington University and lists the drug name, a description of the drug, patent status, and researcher/s name.
- ClinicalTrials.gov. ClinicalTrials.gov is a registry and results database. It allows for searching for specific drugs, diseases, conditions, and study titles among others. It has study data from over 200 countries.
- Cochrane Central Register of Controlled Trials (CENTRAL). CENTRAL provides searchable reports of randomized and quasi-randomized controlled trials as noted in MEDLINE, Embase, and from other published and unpublished sources.
- Drugs@FDA. Drugs@FDA lists most prescription and over-the-counter (OTC) drug products approved since 1939. Drugs@FDA helps consumers find generic equivalents and other possible appropriate alternatives to their approved products as well as the product’s drug label. Drugs@FDA Demo provides an overview of using Drugs@FDA.
- Green Book. The FDA “Green Book” contains a list of all FDA approved animal drug products.
- Orange Book. The FDA “Orange Book” contains drugs approved by FDA under New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs).
- WHO Pharmaceutical Products. WHO Pharmaceutical Products lists current drugs in pharmaceutical use by world region.
- WHO List of Essential Medicines. WHO list of essential medicines provides information on drugs considered essential by the organization
Challenges you may encounter while searching for information:
Access to self-reported researcher or administrative/in-house data may be required to locate documentation.
Articles, books, and other publications in translational science using the indicator:
- Buxton M, Hanney S. How can payback from health services research be assessed? J Health Serv Res Policy 1996;1(1):35-43. doi: 10.1177/135581969600100107.
- Donovan C, Butler L, Butt AJ, et al. Evaluation of the impact of National Breast Cancer Foundation-funded research. Med J Aust. 2014;200(4):214-218. doi: 10.5694/mja13.10798.
- Hanney SR, Watt A, Jones TH, et al. Conducting retrospective impact analysis to inform a medical research charity’s funding strategies: the case of Asthma UK. Allergy Asthma Clin Immunol. 2013;9:17. doi: 10.1186/1710-1492-9-17.
- Kuruvilla S, Mays N, Pleasant A, et al. Describing the impact of health research: a research impact framework. BMC Health Serv Res. 2006 Oct 18;6:134. doi: 10.1186/1472-6963-6-134.